Global Blood Therapeutics Inc (GBT) Insider Sells $158,550.00 in Stock

Global Blood Therapeutics Inc (NASDAQ:GBT) insider Jung Choi sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $52.85, for a total transaction of $158,550.00. Following the completion of the transaction, the insider now directly owns 137,255 shares of the company’s stock, valued at approximately $7,253,926.75. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Jung Choi also recently made the following trade(s):

  • On Monday, December 18th, Jung Choi sold 3,000 shares of Global Blood Therapeutics stock. The stock was sold at an average price of $36.55, for a total transaction of $109,650.00.

Shares of Global Blood Therapeutics Inc (NASDAQ GBT) traded down $1.85 during midday trading on Friday, reaching $57.15. 1,263,606 shares of the company’s stock traded hands, compared to its average volume of 883,543. Global Blood Therapeutics Inc has a 1-year low of $17.70 and a 1-year high of $65.40. The company has a market cap of $2,629.30, a price-to-earnings ratio of -22.41 and a beta of 4.78.

A number of equities research analysts have recently weighed in on the stock. ValuEngine upgraded shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. William Blair began coverage on shares of Global Blood Therapeutics in a report on Tuesday, January 23rd. They issued an “outperform” rating and a $80.00 price objective for the company. HC Wainwright set a $73.00 price target on shares of Global Blood Therapeutics and gave the company a “buy” rating in a report on Thursday, January 11th. Cantor Fitzgerald set a $61.00 price target on shares of Global Blood Therapeutics and gave the company a “buy” rating in a report on Monday, December 11th. Finally, Nomura upped their price target on shares of Global Blood Therapeutics to $91.00 and gave the company a “buy” rating in a report on Monday, December 11th. Two analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Global Blood Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $63.27.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Parametric Portfolio Associates LLC grew its position in shares of Global Blood Therapeutics by 0.9% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 30,943 shares of the company’s stock worth $846,000 after buying an additional 284 shares during the period. Taylor Wealth Management Partners grew its position in shares of Global Blood Therapeutics by 2.7% in the 4th quarter. Taylor Wealth Management Partners now owns 48,865 shares of the company’s stock worth $1,923,000 after buying an additional 1,300 shares during the period. Fiduciary Trust Co. grew its position in shares of Global Blood Therapeutics by 7.8% in the 3rd quarter. Fiduciary Trust Co. now owns 23,580 shares of the company’s stock worth $732,000 after buying an additional 1,701 shares during the period. American International Group Inc. grew its position in shares of Global Blood Therapeutics by 8.1% in the 3rd quarter. American International Group Inc. now owns 24,752 shares of the company’s stock worth $769,000 after buying an additional 1,850 shares during the period. Finally, Alps Advisors Inc. grew its position in shares of Global Blood Therapeutics by 9.3% in the 3rd quarter. Alps Advisors Inc. now owns 43,015 shares of the company’s stock worth $1,336,000 after buying an additional 3,649 shares during the period. Institutional investors and hedge funds own 85.67% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Global Blood Therapeutics Inc (GBT) Insider Sells $158,550.00 in Stock” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://ledgergazette.com/2018/02/12/jung-choi-sells-3000-shares-of-global-blood-therapeutics-inc-gbt-stock.html.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Insider Buying and Selling by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply